Ireland-based B-Secur announces FDA clearance and launch of ‘HeartKey Rhythm Solution’

image credit- shutterstock

B-Secur, a leader in advanced biosensing technology, announced the FDA clearance and launch of HeartKey Rhythm, a suite of electrocardiogram (ECG) algorithms and analytics designed to enhance clinical confidence, streamline industry efficiency, and improve outcomes for cardiac patients.

Powered by B-Secur's innovative signal processing engine, HeartKey Rhythm enhances signal clarity by reducing noise, delivering high-quality ECG data. Specifically targeted at the ambulatory ECG (AECG) market, HeartKey Rhythm's rhythm detection algorithms and signal quality indicators allow clinicians to prioritize their interpretation of data and enable more confident detection of actionable cardiac conditions.

"There is an ever-increasing reliance on ECG data collected outside of a controlled clinical environment," said Adrian Condon, B-Secur's CTO and Co-founder. "Our breakthrough FDA cleared product, HeartKey Rhythm, significantly improves the ECG signal processing and rhythm recognition of ambulatory devices and platforms."
While HeartKey Rhythm is focused on AECG, B-Secur also offers on-chip solutions designed for consumer wearable devices, further supporting the convergence of these technologies in tackling heart disease.